HAG
NBIX icon

HighPoint Advisor Group’s Neurocrine Biosciences NBIX Stock Holding History

HighPoint Advisor Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,838
Closed -$403K – 904
2025
Q4 		$403K Hold
2,838
– – 0.01% 739
2025
Q3 		$398K Sell
2,838
-33
-1% -$4.47K 0.02% 448
2025
Q2 		$361K Buy
2,871
+59
+2% +$6.77K 0.02% 460
2025
Q1 		$302K Buy
2,812
+366
+15% +$46.4K 0.02% 487
2024
Q4 		$286K Buy
2,446
+96
+4% +$11.9K 0.02% 524
2024
Q3 		$287K Buy
2,350
+425
+22% +$58.3K 0.02% 500
2024
Q2 		$272K Sell
1,925
-633
-25% -$86.8K 0.02% 501
2024
Q1 		$348K Buy
2,558
+48
+2% +$6.55K 0.02% 425
2023
Q4 		$352K Buy
+2,510
New +$289K 0.03% 431
2022
Q2 		$207K Buy
+2,178
New +$201K 0.02% 487

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighPoint Advisor Group's NBIX Position: Q1 2026 in Review

HighPoint Advisor Group sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,838 shares — an estimated $403K sold.

HighPoint Advisor Group first reported a position in NBIX in Q2 2022 and held it in 10 quarters. The position peaked at $403K in Q4 2025. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • HighPoint Advisor Group reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • HighPoint Advisor Group sold 2,838 Neurocrine Biosciences shares in Q1 2026, an estimated $403K.
  • HighPoint Advisor Group first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 10 quarters.
  • HighPoint Advisor Group's Neurocrine Biosciences position peaked at $403K in Q4 2025.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.